表紙
市場調查報告書

細胞株和薄膜市場

Cell Line and Membrane Market

出版商 BCC Research 商品編碼 819220
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
細胞株和薄膜市場 Cell Line and Membrane Market
出版日期: 2019年03月29日內容資訊: 英文 176 Pages
簡介

全球細胞株和薄膜市場預計從2018年的1億7,200萬美元以5.1%的年複合成長率擴大,到2023年達到2億2,030萬美元。

本報告提供全球細胞株和薄膜市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介等相關資訊彙整。

第1章 簡介

第2章 摘要和亮點

第3章 市場概要

  • 簡介
  • 市場潛力
  • 相關法規
    • 美國
    • 歐洲
    • 中國
    • 印度
    • 日本
    • 巴西
  • 投資分析
  • 產業成長促進要素
  • 技術進步加速細胞株的放大(Scale-up)
  • 對細胞培養技術的巨額投資
  • 細胞化驗分析的細胞株技術引進擴大
  • 抗體製做的需求擴大
  • 製藥公司,生物科技企業對藥物開發的投資

第4章 各產品市場

  • 細胞株的種類
    • 細胞株和細胞培養
    • 免疫治療細胞株
    • 離子通道細胞株
    • GPCR細胞株
    • 細胞訊號途徑細胞株
    • 遺傳基因剔除細胞株
    • 癌症細胞株
    • 其他
  • 細胞薄膜的種類
    • 天然
    • 合成

第5章 各終端用戶市場

  • 生物醫藥品廠商
  • CRO
  • 學術研究機關
  • 法醫實驗室
  • 食品、飲料廠商
  • 細胞株和細胞培養的應用
  • 使用植物細胞株的優點
  • 食品、飲料製造的微生物
  • 清潔肉的細胞株
  • 診斷中心
  • 在診斷中心用作生物醫學藥物研發研究工具的肺癌細胞株
  • 細胞薄膜蛋白質體學鑑定乳癌的可能性
  • 其他

第6章 各用途市場

  • 藥物研發開發
  • 藥物研發和開發過程的細胞株和薄膜的應用
  • 癌症製藥基因學的細胞株的利用擴大
  • 臨床實驗
  • 基礎研究
  • 研究的細胞株的優點
  • 毒性篩檢
  • 生物醫藥品製造
    • 生物醫藥品製造用人細胞株的使用
    • 生物醫藥品製造用CHO細胞的使用
  • 藥物篩檢
  • 刑事鑑定
  • 細胞株認證
  • 組織工程
  • 組織工程的幹細胞應用

第7章 各地區市場

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第8章 產業結構

第9章 企業簡介

第10章 附錄

目錄
Product Code: BIO178A

Report Highlights:

The global cell line and membrane market should reach $220.3 million by 2023 from $172.0 million in 2018 at a compound annual growth rate (CAGR) of 5.1% for the period 2018 to 2023.

Cell lines as a segment of the global cell line and membrane market is expected to grow from $154.6 million in 2018 to $197.8 million in 2023 at a CAGR of 5.1% for the period 2018 to 2023.

Cell membranes as a segment of the global cell line and membrane market is expected to grow from $17.4 million in 2018 to $22.5 million in 2023 at a CAGR of 5.3% for the period 2018 to 2023.

Report Scope:

The scope of this report is broad and covers various types of products available in the cell line and membrane market and potential application sectors across various industries. The cell line and membrane market is segmented by cell line product type and membrane type. Revenue forecasts from 2018 to 2023 are given for each product, application and end user with estimated values derived from the total revenue of manufacturers.

The report also includes a discussion of the major players across each region in the cell line and membrane market. Further, it explains the major drivers and regional dynamics of the global cell line and membrane market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the cell line and membrane market.

Report Includes:

  • 79 data tables and 60 additional tables
  • Identification of applications of cell lines in drug development, diagnostics, and molecular biology
  • Description of advancements in cell lines for cancer-based therapies
  • Details of CAR-T Cell and immune check point inhibitor therapy
  • Comparative study of autologous vs allogenic cells manufacturing process
  • Explanation of increasing adoption of cell line technologies in cell-based assay and surging demand of antibody production as a driving force to the cell line market
  • Detailed profiles of the major vendors in the global cell line and membrane market, including ATCC, GE Healthcare, Lonza Group Ltd., Sartorius, Thermo Fisher Scientific and Wuxi AppTec

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market Overview

  • Introduction
  • Market Potential
  • Regulatory Framework
    • United States
    • European Union
    • China
    • India
    • Japan
    • Brazil
  • Investment Analysis
  • Industry Growth Drivers
    • Advancement in Technologies Accelerating the Scale-up of Cell Lines
    • High Investment in Cell Culture Technology
    • Increasing Adoption of Cell Line Technologies in Cell-Based Assays
    • Surging Demand for Antibody Production
    • High Investments by Pharmaceutical and Biotechnology Companies in Drug Development

Chapter 4: Market Breakdown by Product

  • Type of Cell Line
    • Development of Cell Lines and Cell Culture
    • Immunotherapy Cell Lines
    • Ion Channel Cell Lines
    • GPCR Cell Lines
    • Cell Signaling Pathway Cell Lines
    • Gene Knockout Cell Lines
    • Cancer Cell Lines
    • Others
  • Type of Cell Membrane
    • Natural
    • Synthetic

Chapter 5: Market Breakdown by End User

  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Forensic Science Laboratories
  • Food and Beverage Companies
    • Application of Cell Lines and Cell Cultures
    • The Benefits of Using Plant Cell Lines:
    • Microbes for Food and Beverage Production
    • Cell Lines in Clean Meat
  • Diagnostic Centers
    • Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research in Diagnostic Centers
    • Cell Membrane Proteomics Can Potentially Identify Breast Cancer
  • Others

Chapter 6: Market Breakdown by Application

  • Drug Discovery and Development
    • Application of Cell Line and Membrane in Drug Discovery and Development Process
    • Surging Utilization of Cell Lines in Cancer Pharmagenomics
    • Clinical Trials
  • Basic Research
    • Benefits of Cell Line in Research
  • Toxicity Screening
  • Biopharmaceutical Production
    • The Use of Human Cell Line for Biopharmaceutical Production
    • The Use of CHO Cells for Biopharmaceutical Production
    • Driver
  • Drug Screening
    • Driver
  • Forensic Testing
    • Cell Line Authentication
  • Tissue Engineering
    • Stem Cell Applications in Tissue Engineering
    • Driver

Chapter 7: Market Breakdown by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • ROAPAC
  • RoW (Rest of the World)
    • Latin America
    • Middle East and Africa

Chapter 8: Cell Line and Membrane Market Industry Structure

  • Procurement of Raw Materials
    • Quality
    • Terms and Conditions
    • Cost Effective Components
  • Manufacturing/Development Process
  • End Users
  • Factors Affecting Cell Line and Membrane Market
  • Innovation within the Industry
    • Various Gene Engineering Approaches
    • Advancements in Cell Lines for Cancer-Based Therapies
    • CAR T-Cell Lines and Immune Checkpoint Inhibitors
  • Autologous vs. Allogenic Cells Manufacturing Process
  • Competitive Analysis

Chapter 9: Company Profiles

  • ABZENA
  • ACM BIOLABS
  • ATCC
  • BD BIOSCIENCES
  • BIOIVT
  • CATALENT INC.
  • CELL BIOLABS INC.
  • CORNING INC.
  • CREATIVE BIOLABS
  • ETUBICS CORP.
  • GE HEALTHCARE
  • IXCELLS BIOTECHNOLOGIES
  • LONZA GROUP LTD.
  • MI BIORESEARCH INC.
  • MERCK MILLIPORE
  • MILTENYI BIOTEC
  • NOVUS BIOLOGICALS
  • ROCKLAND IMMUNOCHEMICALS INC.
  • QUIDEL CORP.
  • SARTORIUS
  • SELEXIS SA
  • THERMO FISHER SCIENTIFIC
  • WUXI APPTEC

List of Tables

  • Summary Table: Global Market for Cell Line and Membrane, by Product, Through 2023
    • Table 1: Investment Analysis
    • Table 2: Investments in Cell Culture Technology
    • Table 3: Regional Analysis of Studies on Antibodies
    • Table 4: Total Global Pharmaceutical R&D Spending, 2015-2022
    • Table 5: Global Cell Line and Membrane Market, by Product, Through 2023
    • Table 6: Key Sources and Description of Biological Contamination of Cell Lines and Membranes
    • Table 7: Some Key Mammalian and Insect Cell Cultures
    • Table 8: List of Animal Cell Lines Used in Research
    • Table 9: Global Cell Line Market, by Type, Through 2023
    • Table 10: Global Cell Line Market, by Region, Through 2023
    • Table 11: NCI-60 Cancer Cell Lines
    • Table 12: Most Common Cancers, by Type, 2018
    • Table 13: Research Grants, by Cancer Type, August 2018
    • Table 14: Global Cell Membrane Market, by Type, Through 2023
    • Table 15: Global Pharmaceutical R&D Spending, 2015-2022
    • Table 16: Global Cell Membrane Market, by Region, Through 2023
    • Table 17: Global Cell Line and Membrane Market, by End User, Through 2023
    • Table 18: Global Biopharmaceutical Companies Market, by Region, Through 2023
    • Table 19: Cell Lines Used in the Production of Biopharmaceuticals
    • Table 20: Global Growth in Pharmaceutical Market, 2015 and 2020
    • Table 21: Global Biologics Spending, 2011 and 2016
    • Table 22: Global Biosimilars Spending, 2011 and 2016
    • Table 23: Global Contract Research Organizations (CROs) Market, by Region, Through 2023
    • Table 24: Drug Development, by CRO, 2017 and 2018
    • Table 25: Global Academic and Research Institutes Market, by Region, Through 2023
    • Table 26: Cell Lines Research and Development in Academic and Research Institutes, 2017 and 2018
    • Table 27: Global Prevalence of Dementia, 2015-2050
    • Table 28: Global Forensic Science Laboratories Market, by Region, Through 2023
    • Table 29: Global Food and Beverage Companies Market, by Region, Through 2023
    • Table 30: Microbial Strains Used in Food and Beverage Industries
    • Table 31: Global Diagnostic Centers Market, by Region, Through 2023
    • Table 32: Global Other End Users Market, by Region, Through 2023
    • Table 33: Global Cell Line and Membrane Market, by Application, Through 2023
    • Table 34: Global Drug Discovery and Development Market, by Region, Through 2023
    • Table 35: International Cancer Research Projects Share, by Region, 2017-2018
    • Table 36: American Chemical Society Grants, by Cancer Type, 2018
    • Table 37: Investment in Cancer Research in Canada, by Cancer Type, 2016
    • Table 38: Drugs in Development, by Disease Type, 2017
    • Table 39: Pharmaceutical Spending, by Country, 2016
    • Table 40: Global Basic Research Market, by Region, Through 2023
    • Table 41: U.S. R&D Funding Share, 2016
    • Table 42: Global Toxicity Screening Market, by Region, Through 2023
    • Table 43: Member Companies of the Pharmaceutical Research and Manufacturers of America R&D Investments (U.S.), 2005-2016
    • Table 44: Investments in Personalized Medicine, 2017 and 2018
    • Table 45: Global Biopharmaceutical Production Market, by Region, Through 2023
    • Table 46: U.S. Food and Drug Administration-Approved Protein Therapeutics, 2015-2016
    • Table 47: Comparison of Human Cell Lines with Other Expression Systems in the Production of Therapeutic Proteins
    • Table 48: Monoclonal Antibodies Approved by the European Medical Agency and Food and Drug Administration for Therapeutic Use Status, 2015-2017
    • Table 49: Pharmaceutical R&D Expenditure in Europe, the U.S. and Japan, 2010 and 2015
    • Table 50: Global Drug Screening Market, by Region, Through 2023
    • Table 51: Advantages and Disadvantages of the Use of Cancer Cell Lines as Models in Cancer Research
    • Table 52: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
    • Table 53: Global Forensic Testing Market, by Region, Through 2023
    • Table 54: Current Status of SNP, STR, and DNA Barcode Technologies as Standard Methods for Assessing the Identity of Cell Lines from Different Species
    • Table 55: Global Tissue Engineering Market, by Region, Through 2023
    • Table 56: NIH Spending Trend on Stem Cell Research, 2015-2018
    • Table 57: Global Cell Line and Membrane Market, by Region, Through 2023
    • Table 58: North American Cell Line and Membrane Market, by Country, Through 2023
    • Table 59: NIH Spending on Stem Cell Research, 2013-2016
    • Table 60: North American Cell Line and Membrane Market, by Product, Through 2023
    • Table 61: NIH Funding for CRISPR-Related Research, 2006-2016
    • Table 62: North American Cell Line and Membrane Market, by End User, Through 2023
    • Table 63: Net Spending on Biologics in the U.S., 2013-2017
    • Table 64: North American Cell Line and Membrane Market, by Application, Through 2023
    • Table 65: Percentage Increase of Spending on Biologics in Canada, 2011-2016
    • Table 66: European Cell Line and Membrane Market, by Country, Through 2023
    • Table 67: Pharmaceutical Industry R&D Expenditures in Selected European Countries
    • Table 68: Cumulative Spending on Biosimilar Medicines in the EU5, 2016-2020
    • Table 69: European Cell Line and Membrane Market, by Product, Through 2023
    • Table 70: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
    • Table 71: European Cell Line and Membrane Market, by End User, Through 2023
    • Table 72: European Cell Line and Membrane Market, by Application, Through 2023
    • Table 73: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
    • Table 74: Asia-Pacific Cell Line and Membrane Market, by Country, Through 2023
    • Table 75: Asia-Pacific Cell Line and Membrane Market, by Product, Through 2023
    • Table 76: Studies Recruiting Under Phase IV, Based on Cell Line
    • Table 77: Number of People with Cancer in China, 2010-2016
    • Table 78: Asia-Pacific Cell Line and Membrane Market, by Application, Through 2023
    • Table 79: Growth in Biotech Industry in India, 2010-2017
    • Table 80: Some of the Approved Biosimilar Products in India
    • Table 81: Growing Number of Cancer Patients in India, 2010-2016
    • Table 82: Asia-Pacific Cell Line and Membrane Market, by End User, Through 2023
    • Table 83: R&D Spending in India, by Top Pharmaceutical Companies, 2016
    • Table 84: List of Biotech Companies Supported by Osaka University in Cell Culture
    • Table 85: Estimated Most Common Cancer Diagnosed, by Type, 2018
    • Table 86: Commonly Diagnosed Cancers in Australia, 2017
    • Table 87: Rest of the World Cell Line and Membrane Market, by Country, Through 2023
    • Table 88: Rest of the World Cell Line and Membrane Market, by Product, Through 2023
    • Table 89: Rest of the World Cell Line and Membrane Market, by End User, Through 2023
    • Table 90: Rest of the World Cell Line and Membrane Market, by Application, Through 2023
    • Table 91: Global Suppliers to Cell Line and Membrane Market
    • Table 92: Some of the Major Cell Line and Membrane Companies
    • Table 93: FDA Center for Drug Evaluation and Research Approved Biologics Based on Cell Lines, 2015
    • Table 94: Some CRISPR-Cas-Based Gene Editing Techniques Used for Manipulation of Various Organisms
    • Table 95: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
    • Table 96: Global CAR T-Cell Therapy Market, by Region, Through 2023
    • Table 97: Global Immune Checkpoint Inhibitor Therapy Market, by Region, Through 2023
    • Table 98: FDA-Approved Immune Checkpoint Inhibitors
    • Table 99: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
    • Table 100: Autologous vs. Allogenic Cells Manufacturing Process
    • Table 101: Abzena: Product Portfolio
    • Table 102: Abzena: Recent Developments
    • Table 103: ACM Biolabs: Product Portfolio
    • Table 104: ACM Biolabs: Recent Developments, January 2018 to December 2018
    • Table 105: ATCC: Product Portfolio
    • Table 106: ATCC: Recent Developments, 2015 to September 2018
    • Table 107: BD Biosciences: Product Portfolio
    • Table 108: BioIVT: Product Portfolio
    • Table 109: BioIVT: Recent Developments, 2015 to September 2018
    • Table 110: Catalent Inc.: Product Portfolio
    • Table 111: Catalent Inc.: Recent Developments, 2015 to September 2018
    • Table 112: Cell Biolabs Inc.: Product Portfolio
    • Table 113: Corning Inc.: Product Portfolio
    • Table 114: Creative Biolabs: Product Portfolio
    • Table 115: Etubics Corp.: Product Portfolio
    • Table 116: Etubics Corp.: Recent Developments, 2015 to September 2018
    • Table 117: GE Healthcare: Product Portfolio
    • Table 118: GE Healthcare: Recent Developments, 2015 to September 2018
    • Table 119: iXCells Biotechnologies: Product Portfolio
    • Table 120: Lonza Group Ltd.: Product Portfolio
    • Table 121: Lonza Group Ltd.: Recent Developments, 2015 to September 2018
    • Table 122: MI Bioresearch Inc.: Product Portfolio
    • Table 123: Merck Millipore: Product Portfolio
    • Table 124: Merck Millipore: Recent Developments, 2015 to September 2018
    • Table 125: Miltenyi Biotec: Product Portfolio
    • Table 126: Miltenyi Biotec: Recent Developments, 2015 to September 2018
    • Table 127: Novus Biologicals: Product Portfolio
    • Table 128: Novus Biologicals: Recent Developments, 2015 to September 2018
    • Table 129: Rockland Immunochemicals Inc.: Product Portfolio
    • Table 130: Rockland Immunochemicals Inc.: Recent Developments, 2015 to September 2018
    • Table 131: Quidel Corp.: Product Portfolio
    • Table 132: Quidel Corp.: Recent Developments, 2015 to September 2018
    • Table 133: Sartorius: Product Portfolio
    • Table 134: Selexis SA: Product Portfolio
    • Table 135: Thermo Fisher Scientific: Product Portfolio
    • Table 136: Thermo Fisher Scientific: Recent Developments, 2015 to September 2018
    • Table 137: WuXi AppTec: Product Portfolio
    • Table 138: WuXi AppTec: Recent Developments, 2015 to June 2018

List of Figures

  • Summary Figure: Global Market for Cell Line and Membrane, by Product, 2017-2023
    • Figure 1: Types of Cell Line Technologies
    • Figure 2: Total Global Pharmaceutical R&D Spending, 2015-2022
    • Figure 3: PhRMA Member Company R&D Expenditures, 2010 and 2016
    • Figure 4: Process of Deriving a Cell Line
    • Figure 5: Type of Cell Lines
    • Figure 6: Process of Growing Cell Lines and Delivering to Patients
    • Figure 7: Production Process of Ion Channel Cell Line
    • Figure 8: GPCR Cell Line Development Process
    • Figure 9: Applications of Cell Signaling Pathway Cell Lines
    • Figure 10: Generation of Knockout Cell Lines
    • Figure 11: Most Common Cancers, by Type, 2018
    • Figure 12: Production Process of Monoclonal Antibodies from Hybridoma Cell Lines
    • Figure 13: Global Pharmaceutical R&D Spending, 2015-2022
    • Figure 14: Common Benefits of Human Cell Lines in the Production of Therapeutic Proteins
    • Figure 15: Biopharmaceutical Production Using Mammalian Cells
    • Figure 16: Global Growth in Pharmaceutical Market, 2015 and 2020
    • Figure 17: Global Biologics Spending, 2011 and 2016
    • Figure 18: Global Biosimilars Spending, 2011 and 2016
    • Figure 19: Cell Lines and Membranes Application in Academic and Research Institutes
    • Figure 20: Global Prevalence of Dementia, 2015-2050
    • Figure 21: Advantages of Short Tandem Repeat Profiling in Cell Line Authentication
    • Figure 22: Workflow for Authentication of Cell Lines
    • Figure 23: Clean Meat Development Process Through Cell Lines
    • Figure 24: Meat Consumption, 2015-2027
    • Figure 25: Workflow Outlines Process of Obtaining Plasma Membrane Proteome of Multiple BC Cell Lines
    • Figure 26: Storage of Cell Lines in Cell Bank
    • Figure 27: Major Factors Driving the Growth of the Cell Line and Membrane Market, by Application
    • Figure 28: International Cancer Research Projects Share, by Region, 2017-2018
    • Figure 29: Drugs Share in Development, by Disease Type, 2017
    • Figure 30: Pharmaceutical Spending, by Country, 2016
    • Figure 31: U.S. R&D Funding Share, 2016
    • Figure 32: Member Company of Pharmaceutical Research and Manufacturers of America R&D Investment (U.S.), 2005-2016
    • Figure 33: Pharmaceutical R&D Expenditure in Europe, U.S. and Japan, 2010 and 2015
    • Figure 34: STR Analysis of Cell Lines
    • Figure 35: The Basic Materials and Processes Needed for Tissue Engineering Technologies
    • Figure 36: NIH Spending Trend on Stem Cell Research, 2015-2018
    • Figure 37: NIH Spending on Stem Cell Research, 2013-2016
    • Figure 38: Net Spending on Biologics in the U.S., 2013-2017
    • Figure 39: Pharmaceutical Industry R&D Expenditure in Selected European Countries
    • Figure 40: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
    • Figure 41: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
    • Figure 42: Number of People with Cancer in China, 2010-2016
    • Figure 43: Growth in Biotech Industry in India, 2010-2017
    • Figure 44: Growing Number of Cancer Patients in India, 2010-2016
    • Figure 45: R&D Spending in India, by Top Pharmaceutical Companies, 2016
    • Figure 46: Japan Pharmaceuticals Industry, 2010-2015
    • Figure 47: Estimated Most Common Cancer Diagnosed, by Type, 2018
    • Figure 48: Industry Structure of the Cell Line and Membrane Market
    • Figure 49: Cell Line Development Flow chart
    • Figure 50: CAR T-Cell Therapy Mechanism
    • Figure 51: Global CAR T-Cell Therapy Market, by Region, 2017-2023
    • Figure 52: Global Immune Checkpoint Inhibitor Therapy Market, by Region, 2017-2023
    • Figure 53: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
    • Figure 54: Competitive Analysis Share for Cell Line and Membrane Market, by Strategies